| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Medicus Pharma Ltd.$0.46
+0.11 (+30.08%)
F 12Pipeline Score Richly Valued Biotech · Clinical
Market Cap
17.00 M
EPS
-1.78
P/E Ratio
-
Value Trade
2.65 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
2.70 M
Operating CF
-8.97 M
Total Assets
7.43 M
Total Liabilities
6.00 M
Equity
1.33 M
D/E Ratio
12,345
-4.76 %
Week
-8.03 %
1 Month
-72.73 %
3 Month
-85.29 %
6 Month
-90.32 %
5 Year
-90.32 %
All Time
Cash Data
Cash Position
6.37 M
Monthly Burn
2.99 M
Runway
1 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
12.19 M
52 Week Range
0.25 - 7.73
% held by Insiders
13.32 %
% held by Institutions
19.63 %
Enterprise Value
14.33 M
Total Shares
25.55 M
Short %
19.64 %
Float Shares
15.20 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F12
Pipeline Score $1M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.1x
rNPV / MCap Top 9%
Micro Cap (rank 825 of 905)
Percentile RankMedicus Pharma Ltd. has significant pipeline risk (12/100), with $387M risk-adjusted pipeline value, led by D-MNA 200µg in Nodular Basal Cell Carcinoma (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D-MNA 200µg Small molecule | Nodular Basal Cell Carcinoma | Phase 2 | NCT06608238 | 19% | $387M | COMPLETED | 90 | - | - | Mar 13, 2026 | - | MEDIUM Jun 4, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
D-MNA (SKNJCT-003) | Basal Cell Carcinoma | Phase 2 | 2025-06-23 | |||
D-MNA (SKNJCT-003) | Basal Cell Carcinoma | Phase 2 | 2025-06-23 | |||
D-MNA (SKNJCT-003) | Basal Cell Carcinoma | Phase 2 | 2025-06-23 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MDCX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Medicus Pharma Ltd. (MDCX) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
MDCX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MDCX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MDCX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MDCX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
MDCX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MDCXMedicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome
Medicus Pharma has submitted a Rare Pediatric Disease Designation request to the FDA for SkinJect®, a microneedle patch aimed at treating basal cell carcinoma in patients with Gorlin Syndrome. This submission follows an earlier Orphan Drug Designation application and is supported by positive Phase 2 study results. The company aims to provide a non-surgical treatment option for this rare condition.
Read more →MDCXMedicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program
Medicus Pharma has announced the initiation of the PRECISION-E2 Phase 2a study to evaluate Teverelix® in women with symptomatic endometriosis. This innovative trial, leveraging the Emirati Genome Program, aims to explore treatment response variability through genomic analyses. The study is expected to provide insights that could transform endometriosis management and support future development in women's health indications.
Read more →MDCXMedicus Pharma Announces $22 Million Non-Dilutive Financing
Medicus Pharma Ltd. has announced a $22 million non-dilutive financing agreement with an institutional investor. The deal will bolster the company's cash position to around $30 million, providing a projected operating runway of over 24 months. The financing includes immediate capital and a structured release of additional funds based on milestone achievements.
Read more →MDCXMedicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response
Medicus Pharma announced positive results from the expanded analysis of its Phase 2 SKNJCT-003 study, which evaluated the efficacy and safety of Doxorubicin Microneedle Array for treating nodular basal cell carcinoma. The analysis showed a clear dose-response relationship and reinforced the drug's therapeutic profile, paving the way for future discussions with the FDA. The findings suggest a shift in treatment approaches, potentially reducing the need for surgical interventions.
Read more →MDCXMedicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill
Medicus Pharma's CEO, Dr. Raza Bokhari, met with lawmakers on Capitol Hill to advocate for critical healthcare initiatives, including Orphan Drug Designation for SkinJect® for Gorlin Syndrome. The discussions highlighted the urgent need for new treatment options for patients suffering from this rare disease. Medicus aims to advance regulatory pathways for SkinJect®, which offers a non-surgical approach to treatment.
Read more →MDCXMedicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome
Medicus Pharma has submitted an Orphan Drug Designation application to the FDA for SkinJect® aimed at treating basal cell carcinoma in patients with Gorlin Syndrome. This submission highlights the company's strategy to address a significant unmet medical need, as current treatment options are limited and often involve invasive procedures. SkinJect® is designed to provide a localized, non-surgical treatment approach, potentially improving patient outcomes in this rare genetic disorder.
Read more →MDCXMedicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset
Medicus Pharma Ltd. clarified the topline results from its Phase 2 study of SkinJect, a microneedle array for treating nodular basal cell carcinoma. The 200µg dose cohort demonstrated significant clinical activity, supporting further development. The company aims to focus on this dosage in upcoming regulatory discussions and potential partnerships.
Read more →MDCXMedicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate
Medicus Pharma has reported positive Phase 2 results for its SkinJect therapy, achieving an 80% overall response rate in patients with nodular basal cell carcinoma. The independent validation by Dr. Babar Rao, a key opinion leader, supports the clinical significance of the data and suggests potential for non-surgical treatment options. The findings indicate a promising avenue for further development and regulatory discussions.
Read more →MDCXMedicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan
Medicus Pharma announced a business update call to discuss promising results from its Phase 2 SkinJect study, which reported an 80% overall response rate in the 200µg cohort. The call will feature insights from Dr. Babar Rao, highlighting the clinical significance of the findings and the potential to alleviate treatment backlogs for basal cell carcinoma. The company is also advancing plans for an AI-enabled clinical development platform.
Read more →MDCXMedicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update
Medicus Pharma Ltd. reported its financial results for 2025, highlighting significant advancements in its clinical pipeline, particularly the completion of the Phase 2 SkinJect study. The company aims to expand into rare diseases and women's health, while also integrating AI-driven clinical development. Despite a strong capital position, concerns remain about ongoing operating losses and the company's future viability without additional financing.
Read more →MDCXMedicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset
Medicus Pharma has reported positive results from its Phase 2 SKNJCT-003 study for SkinJect, a microneedle delivery system for treating basal cell carcinoma. The study showed a 73% clinical clearance rate in the 200-µg treatment cohort, indicating significant efficacy. The company plans to use these results to engage in regulatory discussions with the FDA and pursue strategic partnerships.
Read more →MDCXMedicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort
Medicus Pharma has reported positive topline results from its Phase 2 study SKNJCT-003, which evaluates the efficacy of Doxorubicin Microneedle Array for treating basal cell carcinoma. The 200µg cohort achieved 73% clinical clearance and 40% histological clearance by Day 57. The company plans to discuss these findings in an end of Phase 2 meeting with the FDA in 2026. However, the study was not designed for registrational endpoints, and regulatory approval remains uncertain.
Read more →MDCXMedicus Pharma To Participate in the 38th Annual Roth Conference
Medicus Pharma Ltd. will participate in the 38th Annual Roth Conference from March 22-24, 2026, in Dana Point, California. CEO Dr. Raza Bokhari will discuss the company's clinical development programs, particularly Skinject's potential for Gorlin Syndrome. The company aims to advance its drug development strategy and engage with investors during the event.
Read more →MDCXMedicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk
Medicus Pharma has received FDA clearance to initiate a Phase 2b study of Teverelix, a long-acting GnRH antagonist, in men with advanced prostate cancer and high cardiovascular risk. The study aims to confirm medical castration and evaluate cardiovascular safety. Teverelix is designed to provide immediate receptor antagonism, potentially reducing cardiovascular risks associated with existing therapies.
Read more →MDCXMedicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile
Medicus Pharma Ltd. announced an amendment to its license agreement with LifeArc, reducing the royalty rate on Teverelix from approximately 4% to 2%. This change is expected to enhance the long-term economic profile of Teverelix, a drug aimed at treating Acute Urinary Retention and prostate cancer patients with cardiovascular risks. The amendment preserves global rights and intellectual property control while maintaining operational responsibilities.
Read more →MDCXMedicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026
Medicus Pharma Ltd. will celebrate its first anniversary on Nasdaq with an Opening Bell ceremony on January 22, 2026. The company has focused on executing its clinical development programs, particularly for its SkinJect and Teverelix therapies. Medicus aims to partner with established pharmaceutical firms for late-stage development and commercialization of its assets.
Read more →MDCXMedicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates
Medicus Pharma Ltd. will present at Biotech Showcase 2026, highlighting its SkinJect Phase 2 program. The company aims to secure partnerships while advancing its clinical development. Positive interim results from the SkinJect study indicate over 60% clinical clearance. Medicus is also exploring regulatory pathways and AI collaborations to enhance its clinical strategies.
Read more →MDCXMedicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
Medicus Pharma Ltd. has completed the enrollment of 90 patients for its Phase 2 clinical study (SKNJCT-003) aimed at non-invasively treating basal cell carcinoma (BCC) using Doxorubicin Microneedle Array (D-MNA). The company anticipates releasing topline results in Q1 2026 and plans to request an end-of-phase 2 meeting with the FDA in H1 2026. The study has shown promising interim results, indicating a significant clinical clearance rate.
Read more →MDCXMedicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement
Medicus Pharma Ltd. has entered into a warrant inducement agreement, allowing for the immediate exercise of outstanding Series A and B Warrants. This agreement is expected to generate approximately $5.1 million in gross proceeds. The exercise price has been reduced to $1.92 per share, and new Series C and D Warrants will also be issued. The closing of the transaction is anticipated to occur on December 5, 2025.
Read more →MDCXMedicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President
Medicus Pharma Ltd. has appointed Carolyn Bonner as Chief Financial Officer while she continues as President. This decision aims to ensure leadership continuity following the resignation of Jim Quinlan. The company is advancing its clinical development programs, including promising results from its SKNJCT-003 study for basal cell carcinoma. Additionally, regulatory approvals in the UK support the expansion of its clinical studies.
Read more →MDCXMedicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
Medicus Pharma Ltd. announced a positive interim analysis for its SKNJCT-003 Phase 2 clinical study aimed at treating basal cell carcinoma non-invasively. The study, involving 60 patients across nine sites in the U.S., reported over 60% of subjects achieving complete clinical clearance. The investigational product, D-MNA, showed good tolerance without serious adverse events. The company intends to submit findings to the FDA to discuss the clinical pathway.
Read more →MDCXMedicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
Medicus Pharma Ltd. has announced the submission of a Phase 2 clinical design (SKNJCT-004) to the UAE Department of Health to non-invasively treat basal cell carcinoma (BCC) of the skin. The study will involve 36 patients across four sites in the UAE and will evaluate the efficacy of two dose levels of D-MNA compared to a placebo. The company aims to expand its clinical development program and gather important data on its novel treatment.
Read more →MDCXMedicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
Medicus Pharma has updated on its Phase 2 clinical study SKNJCT-003 for treating nodular basal cell carcinoma, reporting that over 50% of the 60 patients have been randomized. The company plans to complete an interim data analysis by the end of Q1 2025 and aims to discuss the clinical pathway with the FDA in a Type C meeting in Q2 2025. The study evaluates the efficacy of two doses of D-MNA compared to a placebo.
Read more →MDCXMedicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV)
Medicus Pharma Ltd. has entered into a Standby Equity Purchase Agreement allowing it to sell up to $15 million in shares. The company also announced its intention to voluntarily delist from the TSX Venture Exchange, focusing on its Nasdaq listing, which represents the majority of its trading volume. This strategic move aims to enhance its capital markets strategy while continuing its clinical development programs.
Read more →Competitive Position
How MDCX ranks across every disease it competes inCompetitive Position is a premium feature
See how MDCX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial